Commonwealth Equity Services, LLC Provention Bio, Inc. Transaction History

Commonwealth Equity Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$4.52 - $10.57 $8,886 - $20,780	1,966 Added 11.57%	18,964 $200,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $5,038 - $8,255	1,469 Added 9.46%	16,998 $76,000
Q2 2022 Jul 19, 2022	BUY	$3.65 - $7.3 $1,306 - $2,613	358 Added 2.36%	15,529 $62,000
Q1 2022 May 04, 2022	SELL	$3.4 - $7.88 $47 - $110	-14 Reduced 0.09%	15,171 $111,000
Q4 2021 Jan 31, 2022	SELL	$5.59 - $7.39 $20,124 - $26,604	-3,600 Reduced 19.16%	15,185 $85,000
Q3 2021 Oct 29, 2021	BUY	$5.66 - $8.33 $1,069 - $1,574	189 Added 1.02%	18,785 $120,000
Q2 2021 Aug 11, 2021	BUY	$6.71 - $11.04 $4,488 - $7,385	669 Added 3.73%	18,596 $156,000
Q1 2021 May 04, 2021	BUY	$10.12 - $19.45 $52,897 - $101,665	5,227 Added 41.16%	17,927 $188,000
Q4 2020 Feb 11, 2021	BUY	$11.79 - $18.94 $149,733 - $240,538	12,700 New	12,700 $215,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.